IMA
NASDAQ · Pharmaceuticals
Imagenebio Inc
$5.83
-0.17 (-2.83%)
Financial Highlights (FY 2026)
Revenue
2.06M
Net Income
-116,763,222
Gross Margin
—
Profit Margin
-5,668.6%
Rev Growth
-62.9%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 31.5% | 31.5% |
| Operating Margin | -6,056.4% | -5,450.7% | 13.4% | 16.1% |
| Profit Margin | -5,668.6% | -5,385.2% | 10.3% | 13.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.06M | 5.54M | 44.29M | 39.41M |
| Gross Profit | — | — | 13.97M | 12.43M |
| Operating Income | -124,718,948 | -302,226,852 | 5.94M | 6.35M |
| Net Income | -116,763,222 | -282,948,033 | 4.55M | 5.11M |
| Gross Margin | — | — | 31.5% | 31.5% |
| Operating Margin | -6,056.4% | -5,450.7% | 13.4% | 16.1% |
| Profit Margin | -5,668.6% | -5,385.2% | 10.3% | 13.0% |
| Rev Growth | -62.9% | -62.9% | -0.9% | +2.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 19.74M | 17.02M |
| Total Equity | — | — | 39.52M | 44.51M |
| D/E Ratio | — | — | 0.50 | 0.38 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -123,722,461 | -316,468,330 | 9.89M | 9.22M |
| Free Cash Flow | — | — | 3.33M | 3.29M |